Sven Eric Olsson

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. ncbi request reprint Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine
    Sven Eric Olsson
    Karolinska Institute at Danderyds Hospital, SE 182 88 Danderyd, Sweden
    Vaccine 25:4931-9. 2007
  2. ncbi request reprint Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection
    Sven Eric Olsson
    Karolinska Institute at Danderyd Hospital, Stockholm, Sweden
    Hum Vaccin 5:696-704. 2009
  3. ncbi request reprint Anal sphincter lacerations and upright delivery postures--a risk analysis from a randomized controlled trial
    Daniel Altman
    Pelvic Floor Center, Department of Obstetrics and Gynecology, Karolinska Institute Danderyd Hospital, Stockholm, Sweden
    Int Urogynecol J Pelvic Floor Dysfunct 18:141-6. 2007
  4. ncbi request reprint Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
    Luisa L Villa
    Department of Virology, Ludwig Institute for Cancer Research, Sao Paulo, Brazil
    Lancet Oncol 6:271-8. 2005
  5. ncbi request reprint Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18
    Luisa L Villa
    Department of Virology, Ludwig Institute for Cancer Research, R Prof Antonio Prudente 109, 4th Floor, 01509 010 Sao Paulo, SP, Brazil
    Vaccine 24:5571-83. 2006
  6. ncbi request reprint Endometrial safety and bleeding pattern during a five-year treatment with long-cycle hormone therapy
    Inga Stina Odmark
    Department of Clinical Science, Obstetrics and Gynecology, University of Umea, Sweden
    Menopause 12:699-707. 2005

Collaborators

Detail Information

Publications6

  1. ncbi request reprint Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine
    Sven Eric Olsson
    Karolinska Institute at Danderyds Hospital, SE 182 88 Danderyd, Sweden
    Vaccine 25:4931-9. 2007
    ..We evaluated the extent to which the vaccine is able to generate HPV type-specific immune memory...
  2. ncbi request reprint Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection
    Sven Eric Olsson
    Karolinska Institute at Danderyd Hospital, Stockholm, Sweden
    Hum Vaccin 5:696-704. 2009
    ..Vaccine tolerability in this previously infected population was also assessed...
  3. ncbi request reprint Anal sphincter lacerations and upright delivery postures--a risk analysis from a randomized controlled trial
    Daniel Altman
    Pelvic Floor Center, Department of Obstetrics and Gynecology, Karolinska Institute Danderyd Hospital, Stockholm, Sweden
    Int Urogynecol J Pelvic Floor Dysfunct 18:141-6. 2007
    ..To evaluate obstetric sphincter lacerations after a kneeling or sitting position at second stage of labor in a multivariate risk analysis model...
  4. ncbi request reprint Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
    Luisa L Villa
    Department of Virology, Ludwig Institute for Cancer Research, Sao Paulo, Brazil
    Lancet Oncol 6:271-8. 2005
    ....
  5. ncbi request reprint Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18
    Luisa L Villa
    Department of Virology, Ludwig Institute for Cancer Research, R Prof Antonio Prudente 109, 4th Floor, 01509 010 Sao Paulo, SP, Brazil
    Vaccine 24:5571-83. 2006
    ..Following an initial, similar sized decline, anti-HPV responses plateaued and remained stable through end-of-study (3.0 years). No vaccine-related serious adverse experiences were reported...
  6. ncbi request reprint Endometrial safety and bleeding pattern during a five-year treatment with long-cycle hormone therapy
    Inga Stina Odmark
    Department of Clinical Science, Obstetrics and Gynecology, University of Umea, Sweden
    Menopause 12:699-707. 2005
    ..To determine compliance, the incidence of untoward effects, and endometrial safety in postmenopausal women treated with 3-month sequential hormone therapy for up to 5 years...